RESUMO
During the past few years, medical treatments of cancer have improved thanks to the discovery of targeted therapies. These therapies are today widely used in cancer treatment. The mechanism of action of targeted therapies and the adverse effects they induce are different from the classic chemotherapies, and require a specific management. Most of these drugs are taken at home and orally, and as a consequence, general practitioners should be able to manage these side effects. The most current toxicities in general medicine are fatigue, high blood pressure, dermatologic, gastrointestinal and metabolic side effects. These effects, often moderate are frequent and diverse, and can impact the patient's quality of life and reduce treatment compliance. Management of these toxicities should then be well known by general practitioners in order to optimize care and improve patient wellness.
Assuntos
Terapia Biológica/efeitos adversos , Terapia de Alvo Molecular/efeitos adversos , Qualidade de Vida , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Fadiga/induzido quimicamente , Fadiga/prevenção & controle , Gastroenteropatias/induzido quimicamente , Gastroenteropatias/prevenção & controle , Humanos , Hipertensão/induzido quimicamente , Hipertensão/prevenção & controle , Imunossupressores/efeitos adversos , Doenças Metabólicas/induzido quimicamente , Doenças Metabólicas/prevenção & controle , Neoplasias/tratamento farmacológico , Cooperação do Paciente , Inibidores de Proteínas Quinases/efeitos adversos , Dermatopatias/induzido quimicamente , Dermatopatias/prevenção & controle , Resultado do TratamentoAssuntos
Melanoma/terapia , Neoplasias Cutâneas/terapia , Antineoplásicos/uso terapêutico , Quimioterapia Adjuvante , Feminino , Genótipo , Humanos , Masculino , Margens de Excisão , Melanoma/classificação , Melanoma/diagnóstico , Melanoma/patologia , Estadiamento de Neoplasias , Proteínas Proto-Oncogênicas B-raf/genética , Linfonodo Sentinela/patologia , Biópsia de Linfonodo Sentinela , Neoplasias Cutâneas/classificação , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/patologiaRESUMO
PURPOSE: We aimed at investigating whether early metabolic response to corticosteroid therapy may be used as a diagnostic tool to discriminate between cancer and sarcoidosis, a well-known cause of false-positive 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography (FDG-PET) findings in oncology. PROCEDURE: Two cancer patients with biopsy-proven sarcoidosis or sarcoid-like reaction had multiple thoracic FDG foci. After infectious disease had been excluded, patients received oral corticosteroids for 16 and 14 days, respectively, and underwent posttherapeutic FDG-PET examination. RESULTS: Posttreatment PET revealed a complete metabolic response in both patients, and clinical and imaging follow-up showed no sign of cancer progression. CONCLUSION: Early metabolic response to systemic corticosteroid treatment may be used as a tool in the establishment of final diagnosis when sarcoidosis is suspected in a cancer patient and could be capable of differentiating cancer from sarcoidosis in the case of coexisting diseases.